Synapse - Global Drug Intelligence Database

ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings

This report distills the late-breaking and hot-line evidence from the European Society of Cardiology Congress held in Munich, 28–31 August 2026. It provides a side-by-side analysis of seven pivotal trials — CARDIO-TTRansform, ACACIA-HCM, LIBREXIA-ACS, SINGLE-AF, STAREE, PRESC1SE-MI, and CMR GUIDE — spanning ATTR cardiomyopathy, nonobstructive HCM, post-ACS antithrombotic therapy, atrial fibrillation stroke prevention, primary prevention in older adults, ED triage of suspected MI, and ICD-based primary prevention in intermediate-LVEF populations. Built around the underlying numbers, the report presents every trial's sample size, intervention, follow-up, primary endpoint effect estimate (HR/RR/OR with 95% CI and P value), and serious adverse-event profile. A benefit–risk classification grid, safety-signal visualizations, and five interpretive caveats — including the aficamten LVEF-reduction signal, the hypothesis-generating nature of the CARDIO-TTRansform subgroup finding, and the divergence between STAREE's two co-primary endpoints — help readers gauge evidence strength without being misled by isolated P values. Aimed at cardiologists, clinical researchers, and medical affairs and market-access teams, the report closes by clearly separating findings that are clinically actionable now (ACACIA-HCM, SINGLE-AF, STAREE cardiovascular endpoint, PRESC1SE-MI safety) from those that remain hypothesis-generating or non-confirmatory (CARDIO-TTRansform subgroup, LIBREXIA-ACS, CMR GUIDE). A high-density, decision-oriented reference to the strongest cardiovascular evidence out of ESC 2026.

Read →

Oligonucleotide Therapeutics Report: What Patent Intelligence Reveals About the Next Wave of Platform Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Patent Intelligence: who owns the freedom to operate, and where the platform race is headed next. Oligonucleotide therapeutics are entering a new phase of platform competition, not decided by who owns a therapeutic sequence but by who controls the technology around it. As the field moves beyond early rare-disease proof points into common indications with larger end markets, the centre of value is shifting toward the broader stack: chemical modification, conjugation, delivery, manufacturing, target-tissue access, and platform scalability. This shift raises the bar for Intellectual Property (IP) intelligence. Keyword-based patent search is no longer enough because the signal that matters has moved away from the sequence and into the technology around it (chemical modifications, delivery and conjugation disclosures, and process claims), and increasingly into who is emerging as a platform owner. Reading the landscape now means connecting patent, biological, chemical, clinical, and commercial intelligence in one view. This report uses Patsnap Analytics, Bio, and Synapse to examine how oligonucleotide IP is evolving across four strategic questions: • Who owns the core patent estate across approved products, clinical candidates, and enabling platforms? • How are companies protecting platform value through sequence, formulation, new-use, delivery, conjugation, process, and lifecycle claims? • Where is innovation concentrating across chemistry, delivery, manufacturing, geography, and data assets? • What does the 2027–2036 expiry wave unlock for incumbents, fast-followers, and new platform entrants?

Read →

Oligonucleotide Therapeutics Report: What Clinical and Commercial Intelligence Reveals About the Next Phase of Market Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Clinical & Commercial Intelligence: who's leading the pipeline, and who's positioned to win in the clinic. Oligonucleotide therapeutics are no longer a niche rare-disease segment. With 25 approved drugs, clinical development is expanding across ASO, siRNA, CRISPR, and aptamer modalities. There is increased focus on extrahepatic delivery, reduced off-target effects, and the sponsor-collaborator model as levers for commercial differentiation. This report utilises Patsnap Synapse to examine the field through a clinical, competitive-intelligence, and BD/licensing lens, connecting approved drugs, clinical trials, sponsors, therapeutic areas, targets, geographic activity, and deal signals. The analysis shows a field entering clinical and commercial maturity, albeit unevenly across platform technologies. ASO remains the front runner whilst siRNA is catching up fast, thanks to validated liver-directed GalNAc delivery. Meanwhile, CRISPR remains predominantly early-stage by trial volume but reached an important maturity inflection in 2026 with the first positive Phase III readout for an in-vivo gene-editing candidate (lonvoguran ziclumeran), and aptamers activities remain focused on ophthalmology. The deal landscape mirrors the clinical pipeline and the maturity stage of the different technology platforms, with capital flowing toward validated assets, delivery technologies, tissue-access platforms, and modality-specific capabilities. China is also becoming an important signal source across clinical activity, sponsor formation, manufacturing capability, and early-stage partnering. The key takeaway is clear: although the modality is programmable, the market will reward selectivity, choosing where target biology, tissue delivery, indication, development path, manufacturing feasibility, and commercial value align. For clinical, BD/licensing, and CI teams, the priority is early signal detection, identifying the next meaningful asset, partner, platform, or competitive shift before it becomes obvious in the market. With fierce competition and new entrants, this report serves to provide insights on • Research activities and whitespace: from targets to indications, what are drug developers focusing on? • Clinical and deal signals based on modalities • Recent partnerships and collaborations - how you can adapt your alliance strategy globally

Read →